Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence.

Lee CM, Kwon YK, Won JE, Lee JH, Jeong DG, Wie J, Kim WU, Han HD, Park YM

DOI: 10.1186/s12951-026-04892-3
Published: 2026 Aug 7
Container: Journal of nanobiotechnology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12951-026-04892-3,
  title = {Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence.},
  author = {Lee CM and Kwon YK and Won JE and Lee JH and Jeong DG and Wie J and Kim WU and Han HD and Park YM},
  year = {2026},
  journal = {Journal of nanobiotechnology},
  doi = {10.1186/s12951-026-04892-3},
  url = {https://doi.org/10.1186/s12951-026-04892-3}
}

RIS

TY  - JOUR
TI  - Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence.
AU  - Lee CM
AU  - Kwon YK
AU  - Won JE
AU  - Lee JH
AU  - Jeong DG
AU  - Wie J
AU  - Kim WU
AU  - Han HD
AU  - Park YM
PY  - 2026
JO  - Journal of nanobiotechnology
DO  - 10.1186/s12951-026-04892-3
UR  - https://doi.org/10.1186/s12951-026-04892-3
ER  -

APA

CM, L., YK, K., JE, W., JH, L., DG, J., J, W., WU, K., HD, H., & YM, P. (2026). Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence.. Journal of nanobiotechnology. https://doi.org/10.1186/s12951-026-04892-3

Source records

pubmed · retrieved 2026-11-10T12:50:58.209Z